A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a medical technology company focused on (i) diagnostic, ablation and deep brain stimulation technology for brain related conditions such as epilepsy and Parkinson’s disease; (ii) ablation and stimulation for pain management throughout the body; and (iii) drug delivery including diagnostic and stimulation capabilities. We have received 510(k) clearance for four of our devices from the Food and Drug Administration (“FDA”), including: (i) our Evo cortical electrode technology for temporary (less than 30 days) recording, monitoring, and stimulation on the surface of the brain (“Evo Cortical”), (ii) our Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain (“Evo sEEG”), (iii) our OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures (“OneRF Brain Ab
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 8.7M | 9.1M | - | - | - | - |
| Net Income | -6.8M | -3.6M | -12M | -12M | -10.0M | -9.9M |
| EPS | $-0.18 | $-0.09 | $-0.46 | $-0.65 | $-0.63 | $-0.93 |
| Free Cash Flow | 0 | -2.9M | -11M | -13M | -7.8M | -8.7M |
| ROIC | -70.4% | - | - | - | - | - |
| Gross Margin | 54.9% | 56.5% | - | - | - | - |
| Debt/Equity | 0.00 | - | - | - | - | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -7.6M | -4.2M | -12M | -12M | -10M | -10M |
| Operating Margin | -87.7% | -46.5% | - | - | - | - |
| ROE | -106.7% | - | - | - | - | - |
| Shares Outstanding | 51M | 40M | 27M | 18M | 16M | 11M |
NEUROONE MEDICAL TECHNOLOGIES Corp passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 56.5%. Total shareholder yield (buybacks) is 0.3%.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) has a market capitalization of $37M. It is classified as a small-cap stock.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.34%.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported annual revenue of $9 million in its most recent fiscal year, based on SEC EDGAR filings.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) has a net profit margin of -39.6%. The company is currently unprofitable.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported earnings per share (EPS) of $-0.09 in its most recent fiscal year.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) has a 5-year average gross margin of 56.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.